http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 17 Jul 2026 16:15:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Skynner+Michael/26784496.html si-local-file:///var/storage/secattach/20260717/26784496.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Skynner+Michael/26784496.html Fri, 17 Jul 2026 16:15:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Skynner+Michael/26784496.html si-local-file:///var/storage/secattach/20260717/26784496.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Skynner+Michael/26784496.html Fri, 17 Jul 2026 16:15:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Perry+Jennifer+Scott/26784497.html si-local-file:///var/storage/secattach/20260717/26784497.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Perry+Jennifer+Scott/26784497.html Fri, 17 Jul 2026 16:15:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Perry+Jennifer+Scott/26784497.html si-local-file:///var/storage/secattach/20260717/26784497.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Perry+Jennifer+Scott/26784497.html Fri, 17 Jul 2026 16:15:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Hannay+Michael+Charles+Ferguson/26784500.html si-local-file:///var/storage/secattach/20260717/26784500.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Hannay+Michael+Charles+Ferguson/26784500.html Fri, 17 Jul 2026 16:15:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Hannay+Michael+Charles+Ferguson/26784500.html si-local-file:///var/storage/secattach/20260717/26784500.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Hannay+Michael+Charles+Ferguson/26784500.html Fri, 17 Jul 2026 16:15:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Thompson+Travis+Alvin/26784502.html si-local-file:///var/storage/secattach/20260717/26784502.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Thompson+Travis+Alvin/26784502.html Fri, 17 Jul 2026 16:15:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Thompson+Travis+Alvin/26784502.html si-local-file:///var/storage/secattach/20260717/26784502.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Thompson+Travis+Alvin/26784502.html Fri, 17 Jul 2026 16:15:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Thompson+Travis+Alvin/26742535.html si-local-file:///var/storage/secattach/20260707/26742535.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Thompson+Travis+Alvin/26742535.html Tue, 07 Jul 2026 17:00:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Thompson+Travis+Alvin/26742535.html si-local-file:///var/storage/secattach/20260707/26742535.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Thompson+Travis+Alvin/26742535.html Tue, 07 Jul 2026 17:00:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Lee+Kevin/26742539.html si-local-file:///var/storage/secattach/20260707/26742539.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Lee+Kevin/26742539.html Tue, 07 Jul 2026 17:00:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Lee+Kevin/26742539.html si-local-file:///var/storage/secattach/20260707/26742539.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Lee+Kevin/26742539.html Tue, 07 Jul 2026 17:00:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Skynner+Michael/26742540.html si-local-file:///var/storage/secattach/20260707/26742540.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Skynner+Michael/26742540.html Tue, 07 Jul 2026 17:00:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Skynner+Michael/26742540.html si-local-file:///var/storage/secattach/20260707/26742540.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Skynner+Michael/26742540.html Tue, 07 Jul 2026 17:00:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Hannay+Michael+Charles+Ferguson/26742541.html si-local-file:///var/storage/secattach/20260707/26742541.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Hannay+Michael+Charles+Ferguson/26742541.html Tue, 07 Jul 2026 17:00:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Hannay+Michael+Charles+Ferguson/26742541.html si-local-file:///var/storage/secattach/20260707/26742541.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Hannay+Michael+Charles+Ferguson/26742541.html Tue, 07 Jul 2026 17:00:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Perry+Jennifer+Scott/26742543.html si-local-file:///var/storage/secattach/20260707/26742543.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Perry+Jennifer+Scott/26742543.html Tue, 07 Jul 2026 17:00:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Perry+Jennifer+Scott/26742543.html si-local-file:///var/storage/secattach/20260707/26742543.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+02++Filed+by%3A+Perry+Jennifer+Scott/26742543.html Tue, 07 Jul 2026 17:00:00 -0400 BCYC O.36852577 http://www.streetinsider.com/Analyst+Comments/Bicycle+Therapeutics+%28BCYC%29+Reiterated+at+Market+Outperform+by+Citizens+/26594404.html <p>Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $8.00 price target on Bicycle Therapeutics (NASDAQ: BCYC).</p><p>The analyst commented, "We maintain our Market Outperform rating and price target of $8 for Bicycle Therapeutics based on a platform and cash/share analysis. Recently, Bicycle presented updated doseoptimization data from the Duravelo-2 study of zele (Nectin-4 BDC) plus pembro Q3W in mUC. Importantly, the efficacy generated a compelling 58% BICR-confirmed ORR. We view these data as providing a readthrough to the broader platform pipeline spanning both BDCs and radioligand programs. With $559.5MM in cash, a refocus on early-stage programs that could drive http://www.streetinsider.com/Analyst+Comments/Bicycle+Therapeutics+%28BCYC%29+Reiterated+at+Market+Outperform+by+Citizens+/26594404.html Wed, 03 Jun 2026 04:32:48 -0400 BCYC http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+to+Present+Initial+Duravelo-2+Data+at+2026+ASCO+Annual+Meeting/26536450.html <p class="bwalignc"> <i>In the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin at its optimal dose in combination with pembrolizumab demonstrated response rates comparable to published data for standard of care (SOC) in patients with previously untreated metastatic urothelial cancer (mUC)</i> </p><p class="bwalignc"> <i>The optimal dose of zelenectide demonstrated a potentially differentiated safety profile with incidence rates approximately four-fold lower for skin reactions and half that for peripheral neuropathy as published for SOC</i> </p><p class="bwalignc"> <i>Further data from the randomized Phase 2 trial are expected in 2H 2026</i> </p><p class="bwalignc"> <i>In a separate Phase 1 trial (Duravelo-1) in previously untreated, cisplatin-ineligible mUC, zelenectide in combination http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+to+Present+Initial+Duravelo-2+Data+at+2026+ASCO+Annual+Meeting/26536450.html Thu, 21 May 2026 17:00:00 -0400 A.50216726 BCYC O.21612337 O.36852577 http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+to+Present+Initial+Duravelo-2+Data+at+2026+ASCO+Annual+Meeting/26536450.html <p class="bwalignc"> <i>In the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin at its optimal dose in combination with pembrolizumab demonstrated response rates comparable to published data for standard of care (SOC) in patients with previously untreated metastatic urothelial cancer (mUC)</i> </p><p class="bwalignc"> <i>The optimal dose of zelenectide demonstrated a potentially differentiated safety profile with incidence rates approximately four-fold lower for skin reactions and half that for peripheral neuropathy as published for SOC</i> </p><p class="bwalignc"> <i>Further data from the randomized Phase 2 trial are expected in 2H 2026</i> </p><p class="bwalignc"> <i>In a separate Phase 1 trial (Duravelo-1) in previously untreated, cisplatin-ineligible mUC, zelenectide in combination http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+to+Present+Initial+Duravelo-2+Data+at+2026+ASCO+Annual+Meeting/26536450.html Thu, 21 May 2026 17:00:00 -0400 A.50216726 BCYC O.21612337 O.36852577 http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+to+Present+Initial+Duravelo-2+Data+at+2026+ASCO+Annual+Meeting/26536450.html <p class="bwalignc"> <i>In the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin at its optimal dose in combination with pembrolizumab demonstrated response rates comparable to published data for standard of care (SOC) in patients with previously untreated metastatic urothelial cancer (mUC)</i> </p><p class="bwalignc"> <i>The optimal dose of zelenectide demonstrated a potentially differentiated safety profile with incidence rates approximately four-fold lower for skin reactions and half that for peripheral neuropathy as published for SOC</i> </p><p class="bwalignc"> <i>Further data from the randomized Phase 2 trial are expected in 2H 2026</i> </p><p class="bwalignc"> <i>In a separate Phase 1 trial (Duravelo-1) in previously untreated, cisplatin-ineligible mUC, zelenectide in combination http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+to+Present+Initial+Duravelo-2+Data+at+2026+ASCO+Annual+Meeting/26536450.html Thu, 21 May 2026 17:00:00 -0400 A.50216726 BCYC O.21612337 O.36852577 http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+to+Present+Initial+Duravelo-2+Data+at+2026+ASCO+Annual+Meeting/26536450.html <p class="bwalignc"> <i>In the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin at its optimal dose in combination with pembrolizumab demonstrated response rates comparable to published data for standard of care (SOC) in patients with previously untreated metastatic urothelial cancer (mUC)</i> </p><p class="bwalignc"> <i>The optimal dose of zelenectide demonstrated a potentially differentiated safety profile with incidence rates approximately four-fold lower for skin reactions and half that for peripheral neuropathy as published for SOC</i> </p><p class="bwalignc"> <i>Further data from the randomized Phase 2 trial are expected in 2H 2026</i> </p><p class="bwalignc"> <i>In a separate Phase 1 trial (Duravelo-1) in previously untreated, cisplatin-ineligible mUC, zelenectide in combination http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+to+Present+Initial+Duravelo-2+Data+at+2026+ASCO+Annual+Meeting/26536450.html Thu, 21 May 2026 17:00:00 -0400 A.50216726 BCYC O.21612337 O.36852577 http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+to+Present+Initial+Duravelo-2+Data+at+2026+ASCO+Annual+Meeting/26536450.html <p class="bwalignc"> <i>In the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin at its optimal dose in combination with pembrolizumab demonstrated response rates comparable to published data for standard of care (SOC) in patients with previously untreated metastatic urothelial cancer (mUC)</i> </p><p class="bwalignc"> <i>The optimal dose of zelenectide demonstrated a potentially differentiated safety profile with incidence rates approximately four-fold lower for skin reactions and half that for peripheral neuropathy as published for SOC</i> </p><p class="bwalignc"> <i>Further data from the randomized Phase 2 trial are expected in 2H 2026</i> </p><p class="bwalignc"> <i>In a separate Phase 1 trial (Duravelo-1) in previously untreated, cisplatin-ineligible mUC, zelenectide in combination http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+to+Present+Initial+Duravelo-2+Data+at+2026+ASCO+Annual+Meeting/26536450.html Thu, 21 May 2026 17:00:00 -0400 A.50216726 BCYC O.21612337 O.36852577 http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+to+Present+Initial+Duravelo-2+Data+at+2026+ASCO+Annual+Meeting/26536450.html <p class="bwalignc"> <i>In the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin at its optimal dose in combination with pembrolizumab demonstrated response rates comparable to published data for standard of care (SOC) in patients with previously untreated metastatic urothelial cancer (mUC)</i> </p><p class="bwalignc"> <i>The optimal dose of zelenectide demonstrated a potentially differentiated safety profile with incidence rates approximately four-fold lower for skin reactions and half that for peripheral neuropathy as published for SOC</i> </p><p class="bwalignc"> <i>Further data from the randomized Phase 2 trial are expected in 2H 2026</i> </p><p class="bwalignc"> <i>In a separate Phase 1 trial (Duravelo-1) in previously untreated, cisplatin-ineligible mUC, zelenectide in combination http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+to+Present+Initial+Duravelo-2+Data+at+2026+ASCO+Annual+Meeting/26536450.html Thu, 21 May 2026 17:00:00 -0400 A.50216726 BCYC O.21612337 O.36852577